PL3452485T3 - Inhibitory arginazy oraz ich zastosowania terapeutyczne - Google Patents

Inhibitory arginazy oraz ich zastosowania terapeutyczne

Info

Publication number
PL3452485T3
PL3452485T3 PL17721137T PL17721137T PL3452485T3 PL 3452485 T3 PL3452485 T3 PL 3452485T3 PL 17721137 T PL17721137 T PL 17721137T PL 17721137 T PL17721137 T PL 17721137T PL 3452485 T3 PL3452485 T3 PL 3452485T3
Authority
PL
Poland
Prior art keywords
therapeutic applications
arginase inhibitors
arginase
inhibitors
therapeutic
Prior art date
Application number
PL17721137T
Other languages
English (en)
Inventor
Roman BŁASZCZYK
Julita NOWICKA
Bartłomiej Borek
Joanna BRZEZIŃSKA
Anna GZIK
Marek DZIĘGIELEWSKI
Adam Golebiowski
Karol JĘDRZEJCZAK
Krzysztof MATYSZEWSKI
Jacek OLCZAK
Original Assignee
Oncoarendi Therapeutics S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncoarendi Therapeutics S.A. filed Critical Oncoarendi Therapeutics S.A.
Publication of PL3452485T3 publication Critical patent/PL3452485T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL17721137T 2016-05-04 2017-05-02 Inhibitory arginazy oraz ich zastosowania terapeutyczne PL3452485T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662331550P 2016-05-04 2016-05-04
PL417066A PL417066A1 (pl) 2016-05-04 2016-05-04 Inhibitory arginazy oraz ich zastosowania terapeutyczne
US201762444669P 2017-01-10 2017-01-10
PCT/EP2017/060413 WO2017191130A2 (en) 2016-05-04 2017-05-02 Arginase inhibitors and their therapeutic applications
EP17721137.2A EP3452485B1 (en) 2016-05-04 2017-05-02 Arginase inhibitors and their therapeutic applications

Publications (1)

Publication Number Publication Date
PL3452485T3 true PL3452485T3 (pl) 2021-04-19

Family

ID=60190450

Family Applications (2)

Application Number Title Priority Date Filing Date
PL417066A PL417066A1 (pl) 2016-05-04 2016-05-04 Inhibitory arginazy oraz ich zastosowania terapeutyczne
PL17721137T PL3452485T3 (pl) 2016-05-04 2017-05-02 Inhibitory arginazy oraz ich zastosowania terapeutyczne

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL417066A PL417066A1 (pl) 2016-05-04 2016-05-04 Inhibitory arginazy oraz ich zastosowania terapeutyczne

Country Status (24)

Country Link
US (3) US10391077B2 (pl)
EP (1) EP3452485B1 (pl)
JP (1) JP6971477B2 (pl)
KR (1) KR102374788B1 (pl)
CN (1) CN109415387B (pl)
AU (1) AU2017259887B2 (pl)
BR (1) BR112018072545B1 (pl)
CA (1) CA3022482C (pl)
CL (1) CL2018003132A1 (pl)
CO (1) CO2018013077A2 (pl)
DK (1) DK3452485T3 (pl)
ES (1) ES2834065T3 (pl)
HR (1) HRP20201821T1 (pl)
HU (1) HUE052468T2 (pl)
IL (1) IL262387B (pl)
LT (1) LT3452485T (pl)
MX (1) MX378806B (pl)
PE (1) PE20181924A1 (pl)
PH (1) PH12018501976A1 (pl)
PL (2) PL417066A1 (pl)
SA (1) SA518400356B1 (pl)
SG (1) SG11201807974QA (pl)
SI (1) SI3452485T1 (pl)
WO (1) WO2017191130A2 (pl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS54750B1 (sr) 2010-10-26 2016-10-31 Mars Inc Borati kao inhibitori arginaze
US10070649B2 (en) 2013-01-30 2018-09-11 Agrofresh Inc. Volatile applications against pathogens
US11039617B2 (en) 2013-01-30 2021-06-22 Agrofresh Inc. Large scale methods of uniformly coating packaging surfaces with a volatile antimicrobial to preserve food freshness
DK3368541T3 (da) 2015-10-30 2020-06-29 Calithera Biosciences Inc Sammensætninger og metoder til inhibiering af arginaseaktivitet
NZ745681A (en) 2016-03-07 2022-05-27 Agrofresh Inc Synergistic methods of using benzoxaborole compounds and preservative gases as an antimicrobial for crops
PL417066A1 (pl) * 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
EP3842442B1 (en) 2016-12-22 2023-11-01 Precision Pharmaceuticals, Inc. Compositions and methods for inhibiting arginase activity
CN117186134A (zh) 2018-02-17 2023-12-08 阿斯利康(瑞典)有限公司 精氨酸酶抑制剂及其使用方法
US12054500B2 (en) * 2018-03-05 2024-08-06 Arcus Biosciences, Inc. Arginase inhibitors
US12215116B2 (en) 2018-03-13 2025-02-04 Merck Sharp & Dohme Llc Arginase inhibitors and methods of use
WO2019186497A1 (en) 2018-03-29 2019-10-03 Oncoarendi Therapeutics S.A. Dipeptide piperidine derivatives
US11274111B2 (en) 2018-06-20 2022-03-15 Merck Sharp & Dohme Corp. Arginase inhibitors and methods of use
WO2020102646A2 (en) 2018-11-16 2020-05-22 Arcus Biosciences, Inc. Inhibitors of arg1 and/or arg2
WO2020131598A1 (en) * 2018-12-18 2020-06-25 Merck Sharp & Dohme Corp. Arginase inhibitors and methods of use
CN115135385B (zh) 2019-11-12 2024-05-10 纳米医疗有限公司 用于治疗癌症的含有ido拮抗剂前药的调配的和/或共同调配的脂质体组合物及其方法
WO2021141751A1 (en) * 2020-01-07 2021-07-15 Merck Sharp & Dohme Corp. Arginase inhibitors and methods of use
TW202228720A (zh) * 2020-12-22 2022-08-01 波蘭商昂科艾倫迪治療法股份公司 精胺酸酶抑制劑及其使用方法
WO2024209358A1 (en) 2023-04-06 2024-10-10 Molecure S.A. Process for the production of (1r,2s,5r)-1-amino-5-[2-(dihydroxyboranyl)ethyl]-2-[(dimethylamino)methyl]cyclohexane-1-carboxylic acid

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ241954A (en) 1991-03-15 1994-01-26 Amgen Inc Compositions of g-csf for pulmonary administration.
US5451569A (en) 1994-04-19 1995-09-19 Hong Kong University Of Science And Technology R & D Corporation Limited Pulmonary drug delivery system
AU9797998A (en) 1997-10-10 1999-05-03 Trustees Of The University Of Pennsylvania, The Compositions and methods for inhibiting arginase activity
EP1604977A1 (en) 2004-06-02 2005-12-14 Faust Pharmaceuticals CIS pyrrolidinyl derivatives and their uses
EP1604978A1 (en) 2004-06-02 2005-12-14 Faust Pharmaceuticals Trans pyrrolidinyl derivatives and their pharmaceutical uses
MX2009005370A (es) 2006-11-21 2009-10-16 Univ Groningen Uso de inhibidores de arginasa en el tratamiento de asma y rinitis alergica.
TR201910726T4 (tr) 2009-01-26 2019-08-21 Astrazeneca Uk Ltd Arginaz inhibitörleri ve kullanım yöntemleri.
BR112012027034B1 (pt) 2010-04-22 2020-10-13 Mars, Incorporated compostos inibidores de arginase, composição farmacêutica compreendendo o referido composto, método in vitro para inibição de arginase i e ii e uso do referido composto
WO2012025155A1 (en) 2010-08-26 2012-03-01 Novartis Ag Hydroxamate-based inhibitors of deacetylases
RS54750B1 (sr) 2010-10-26 2016-10-31 Mars Inc Borati kao inhibitori arginaze
CN103402549A (zh) 2010-12-31 2013-11-20 考瑞多制药公司 精氨酸酶抑制剂及其使用方法
AU2012326109A1 (en) 2011-10-19 2014-05-29 Mars, Incorporated Inhibitors of arginase and their therapeutic applications
IN2014DN09678A (pl) * 2012-04-18 2015-07-31 Mars Inc
PT2872515T (pt) 2012-07-13 2016-07-27 Janssen Sciences Ireland Uc Purinas macrocíclicas para o tratamento de infeções virais
PL410665A1 (pl) 2014-12-29 2016-07-04 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
WO2016210106A1 (en) 2015-06-23 2016-12-29 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
DK3368541T3 (da) 2015-10-30 2020-06-29 Calithera Biosciences Inc Sammensætninger og metoder til inhibiering af arginaseaktivitet
PL417066A1 (pl) * 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
US11291674B2 (en) 2016-11-08 2022-04-05 Calithera Biosciences, Inc. Arginase inhibitor combination therapies
EP3743510A1 (en) 2018-01-28 2020-12-02 Universite De Geneve Arginase suppression for cancer treatment

Also Published As

Publication number Publication date
CA3022482C (en) 2024-06-11
US10912755B2 (en) 2021-02-09
PL417066A1 (pl) 2017-11-06
KR20190015250A (ko) 2019-02-13
LT3452485T (lt) 2020-12-28
PH12018501976A1 (en) 2019-07-01
JP2019518726A (ja) 2019-07-04
PE20181924A1 (es) 2018-12-11
CN109415387B (zh) 2021-08-27
EP3452485A2 (en) 2019-03-13
CN109415387A (zh) 2019-03-01
KR102374788B1 (ko) 2022-03-15
SA518400356B1 (ar) 2022-01-19
BR112018072545A2 (pt) 2019-06-25
US10391077B2 (en) 2019-08-27
ES2834065T3 (es) 2021-06-16
AU2017259887B2 (en) 2022-03-17
AU2017259887A1 (en) 2018-09-27
MX2018013387A (es) 2019-02-28
US20210260019A1 (en) 2021-08-26
US20190365701A1 (en) 2019-12-05
IL262387A (en) 2018-12-31
CL2018003132A1 (es) 2019-02-22
SG11201807974QA (en) 2018-10-30
EP3452485B1 (en) 2020-09-09
CA3022482A1 (en) 2017-11-09
US20170319536A1 (en) 2017-11-09
JP6971477B2 (ja) 2021-11-24
WO2017191130A4 (en) 2018-03-01
MX378806B (es) 2025-03-11
SI3452485T1 (sl) 2021-01-29
NZ746211A (en) 2024-12-20
CO2018013077A2 (es) 2019-04-30
IL262387B (en) 2021-10-31
HUE052468T2 (hu) 2021-04-28
US12053451B2 (en) 2024-08-06
WO2017191130A2 (en) 2017-11-09
BR112018072545B1 (pt) 2022-08-23
DK3452485T3 (da) 2020-11-09
HRP20201821T1 (hr) 2021-04-16
WO2017191130A3 (en) 2017-12-14

Similar Documents

Publication Publication Date Title
IL262387A (en) Arginase inhibitors and their treatment applications
IL265922A (en) tyk2 inhibitors and uses thereof
IL266109A (en) tyk2 inhibitors and uses thereof
PL3240777T3 (pl) Inhibitory arginazy oraz ich zastosowania terapeutyczne
IL267291A (en) Actonucleotidase inhibitors and methods of using them
IL258970A (en) Bivalent bromodomain inhibitors and their uses
IL280863A (en) Autotaxin inhibitors and uses thereof
GB201605126D0 (en) Inhibitors and their uses
IL263949A (en) Complement inhibitors and their uses
SI3532459T1 (sl) Zaviralci LSD1 in njihove medicinske uporabe
PL3443010T3 (pl) NOWE PRZECIWCIAŁA ANTY-SIRPa I ICH ZASTOSOWANIA TERAPEUTYCZNE
KR20180084747A (ko) Galgt2 유전자 치료 방법 및 물질
SI3621694T1 (sl) Zaviralci lrrc33 in njihove uporabe
IL255530A (en) Efflux-pump inhibitors and therapeutic uses thereof
IL254916A0 (en) Inhibitors and their uses
ZA201801482B (en) Modified cytotoxins and their therapeutic use
EP3302530A4 (en) Cdh26 based therapeutic agents and their use
IL266344A (en) Inhibitors of mtor-deptor interactions and methods of use thereof
ZA201803212B (en) Gelatinase inhibitors and use thereof
ZA201808008B (en) Arginase inhibitors and their therapeutic applications
GB201505975D0 (en) Inhibitors and their uses
GB201505971D0 (en) Inhibitors and their uses